alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               SEP-30-1998
<CASH>                                       3,703,884
<SECURITIES>                                         0
<RECEIVABLES>                                6,303,148
<ALLOWANCES>                                   193,373
<INVENTORY>                                          0
<CURRENT-ASSETS>                            11,763,583
<PP&E>                                     158,592,478
<DEPRECIATION>                            (25,514,456)
<TOTAL-ASSETS>                             153,535,637
<CURRENT-LIABILITIES>                       12,265,954
<BONDS>                                    132,548,782
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        27,270
<OTHER-SE>                                 (8,705,817)
<TOTAL-LIABILITY-AND-EQUITY>               153,535,637
<SALES>                                     23,321,507
<TOTAL-REVENUES>                            23,502,698
<CGS>                                        9,551,700
<TOTAL-COSTS>                               22,591,207
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                              (98,281)
<INTEREST-EXPENSE>                           9,976,574
<INCOME-PRETAX>                            (8,924,563)
<INCOME-TAX>                               (3,055,000)
<INCOME-CONTINUING>                        (5,869,563)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (5,869,563)
<EPS-PRIMARY>                                   (2.15)
<EPS-DILUTED>                                     0.00
        

</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                       2,129,631
<SECURITIES>                                         0
<RECEIVABLES>                                2,112,003
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                     102,053,374
<DEPRECIATION>                            (46,510,462)
<TOTAL-ASSETS>                             137,339,223
<CURRENT-LIABILITIES>                        9,009,127
<BONDS>                                    100,000,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                (52,547,803)
<TOTAL-LIABILITY-AND-EQUITY>               137,339,223
<SALES>                                     45,227,338
<TOTAL-REVENUES>                            45,227,338
<CGS>                                       25,735,732
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                          13,422,670
<INCOME-PRETAX>                           (10,791,799)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                              (10,791,799)
<EPS-BASIC>                                        0
<EPS-DILUTED>                                        0


</TABLE>
No. 67789.

#### Maher & Company *v.*United States,

protest 61/24833-16449 (New Orleans).

Opinion by

Wilson, J.

In accordance with stipulation of counsel that the merchandise and issues are similar in all material respects to those involved in *Falcon Sales Company*and *J. J. Murphy & Co.*v. *United States*(47 Cust. Ct. 129, C.D. 2292), the claim of the plaintiff was sustained.
II 

115TH CONGRESS 

1ST SESSION S. 1292 

To amend the State Department Basic Authorities Act of 1956 to monitor 

and combat anti-Semitism globally, and for other purposes. 

IN THE SENATE OF THE UNITED STATES 

JUNE 6, 2017 

Mr. RUBIO (for himself and Mrs. GILLIBRAND) introduced the following bill; 

which was read twice and referred to the Committee on Foreign Relations 

A BILL 

To amend the State Department Basic Authorities Act of 

1956 to monitor and combat anti-Semitism globally, and 

for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Special Envoy to Mon5 itor and Combat Anti-Semitism Act of 2017’’. 

6 SEC. 2. FINDING. 

7 Congress finds that since the Global Anti-Semitism 

8 Review Act of 2004 was enacted, in many foreign coun9 tries acts of anti-Semitism have been frequent and wide 

10 in scope, the perpetrators and variety of threats to Jewish 


lotter on DSKBCFDHB2PROD with BILLS
2 

•S 1292 IS

1 communities and their institutions have proliferated, and 

2 in some countries anti-Semitic attacks have increased in 

3 frequency, scope, violence, and deadliness. 

4 SEC. 3. MONITORING AND COMBATING ANTI-SEMITISM. 

5 Subsection (a) of section 59 of the State Department 

6 Basic Authorities Act of 1956 (22 U.S.C. 2731) is amend7 ed— 

8 (1) in paragraph (2)— 

9 (A) in subparagraph (A)— 

10 (i) by inserting before the period at 

11 the end the following: ‘‘, who shall be ap12 pointed by the President, by and with the 

13 advice and consent of the Senate’’; and 

14 (ii) by adding at the end the following 

15 new sentence: ‘‘The Special Envoy shall re16 port directly to the Secretary.’’; and 

17 (B) in subparagraph (B)— 

18 (i) by striking the first sentence; and 

19 (ii) in the third sentence, by striking 

20 ‘‘The Secretary may allow such officer or 

21 employee to retain the position (and the 

22 responsibilities associated with such posi23 tion)’’ and inserting ‘‘Such officer or em24 ployee may not retain the position (or the 


lotter on DSKBCFDHB2PROD with BILLS
3 

•S 1292 IS

1 responsibilities associated with such posi2 tion)’’; and 

3 (2) by adding at the end the following new 

4 paragraphs: 

5 ‘‘(3) DUTIES.—The Special Envoy shall serve 

6 as the primary advisor to, and coordinate efforts 

7 across, the United States Government relating to 

8 monitoring and combating anti-Semitism and anti9 Semitic incitement that occur in foreign countries. 

10 ‘‘(4) RANK AND STATUS OF AMBASSADOR.— 

11 The Special Envoy shall have the rank of ambas12 sador. 

13 ‘‘(5) QUALIFICATIONS.—The Special Envoy 

14 should be a person of recognized distinction in the 

15 field of— 

16 ‘‘(A) combating anti-Semitism; or 

17 ‘‘(B) religious freedom.’’. 

Æ 


lotter on DSKBCFDHB2PROD with BILLS
March 24, 2015

Mr. Scott Dennison

Manager of Risk and Crowd Services

SFX Entertainment

13622 East Westland Road

Scottsdale, AZ 85262

Dear Mr. Dennison:

This letter is to inform you that we are unable to process your request for an exemption. It 

explains why we cannot process your request and what you should do in the next 30 days.

Why We Cannot Process Your Request

We entered your February 17, 2015 exemption request on behalf of SFX Entertainment into 

the public docket (No. FAA-2015-0404), but we are unable to process your request any 

further. The information you sent does not comply with the requirements of § 11.81 (copy 

enclosed). For us to consider the request any further, you must send us all of the following:

• The specific section or sections of 14 CFR from which you seek relief and the extent of 

the relief you seek.

• Any additional information, views, or arguments available to support your request.

What You Should Do

If you want us to process your request any further, you must send the information described 

earlier to reach us within 30 days. Please note that § 11.63(d) requires you to send your 

petition for exemption at least 120 days before the proposed effective date of the exemption.
2

If We Do Not Hear From You

If we do not hear from you within 30 days, we will close the docket without notifying you 

further. If you have any questions or require additional time, you may call (202) 267-9521.

Sincerely,

/s/

Jake Troutman

Program Analyst, Airmen and 

 Airspace Rules Division

Enclosure
Case 2:04-cr-00475-AB Document 150 Filed 09/27/12 Page 1 of 2
Case 2:04-cr-00475-AB Document 150 Filed 09/27/12 Page 2 of 2
<PAGE>
                                                                               .
                                                                               .
                                                                               .

Western Reserve Bancorp, Inc.
Exhibit 11--Earnings per Share

<TABLE>
<CAPTION>
                                           Three months ended June 30,     Six months ended June 30,
                                           ---------------------------     -------------------------
                                              2003            2002           2003            2002
                                           ----------      -----------     ---------       ---------
<S>                                       <C>             <C>             <C>             <C>
Numerator:
 Net income                                $ 94,527        $107,082        $229,578        $234,583
Denominator:
 Denominator for basic earnings per
  share--weighted-average shares            388,052         388,052         388,052         388,052
 Effect of dilutive securities:
  Nonqualified stock options                  9,291           7,530           9,291           7,530
                                           --------        --------        --------        --------
 Denominator for diluted earnings
  per share                                 397,343         395,582         397,343         395,582
                                            =======         =======         =======         =======
Basic earnings per share                   $   0.24        $   0.28        $   0.59        $   0.60
                                           ========        ========        ========        ========
Diluted earnings per share                 $   0.24        $   0.27        $   0.58        $   0.59
                                           ========        ========        ========        ========


</TABLE>
##### 



Exhibit 32.1 Certification of Chief Executive Officer Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the
Sarbanes-Oxley Act of 2002, the undersigned officer of United Defense
Industries, Inc. (the Company) hereby certifies, to such officers knowledge,
that: (i) the accompanying Quarterly Report on Form 10-Q of the Company for
the fiscal quarter ended June 30, 2004 (the Report) fully complies with
the requirements of Section 13(a) or Section 15(d), as applicable, of the
Securities Exchange Act of 1934, as amended; and (ii) the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company. Dated: August 2, 2004
    
    /s/ Thomas W. RabautThomas W. Rabaut
President and Chief Executive Officer
 The foregoing certification is being furnished solely to accompany the Report
pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18
of the Securities Exchange Act of 1934, as amended, and is not to be
incorporated by reference into any filing of the Company, whether made before
or after the date hereof, regardless of any general incorporation language in
such filing.
Exhibit 15.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation
by reference in the Registration Statement (Form F-3, No. 333-182394) of América Móvil, S.A.B. de C.V., of our reports dated April 22, 2013, with respect to the consolidated financial statements of América
Móvil, S.A.B. de C.V. and subsidiaries, and the effectiveness of internal control over financial reporting of América Móvil, S.A.B. de C.V., included in this Annual Report on Form 20-F for the year ended December 31, 2012.



Mancera, S.C.A member practice ofErnst & Young Global/s/ Omero Campos SeguraC.P.C. Omero Campos Segura


Mexico City, Mexico

April 30, 2013
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Center for Advancing Translational Sciences Special Emphasis Panel; Preclinical Proof of Concept Studies for Rare Diseases (R21) Review Meeting.                    

*Date:*                         January 24-25, 2024.                    

*Time:*                         9:00 a.m. to 5:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).                    

*Contact Person:*                         Carol (Chang-Sook) Kim, Ph.D., Scientific Review Administrator, Scientific Review Branch, Division of Extramural Activities, National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, MSC 4874 Bethesda, MD 20892, (301) 402-1744,                         *carol.kim@nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: November 8, 2023.

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-25070 Filed 11-13-23; 8:45 am]

BILLING CODE 4140-01-P
May 9, 1962

No. 66751.

#### W. J. Byrnes & Co., Inc., and S. Schonfeld Co., Inc. *v.*United States,

protest 59/9543.

Protest abandoned March 27, 1962. (Not published.) (Initial No. 59/22139.) Plaintiffs’ application for rehearing granted.
854098.12.01 10/16/02 1:49 PM

IN THE UNITED STATES DISTRICT COURT

FOR THE EASTERN DISTRICT OF PENNSYLVANIA

KIMBERLY TKACS :

: CIVIL ACTION NO. 02-4294

Plaintiff, :

:

v. :

:

BAYER CORPORATION;

BAYER AG;

GLAXOSMITHKLINE, PLC;

GLAXOSMITHKLINE;

SMITHKLINE BEECHAM

:

:

:

:

:

ENTRY OF APPEARANCE

:

Defendants. :

ENTRY OF APPEARANCE

To the Clerk of the Court:

Kindly enter the appearances of Hope S. Freiwald, Aline Fairweather, Erin

Brennan and Kirstin J. Miller as attorneys for defendant SmithKline Beecham Corporation d/b/a

GlaxoSmithKline.

Respectfully Submitted,

_____________________________ _____________________________

Hope S. Freiwald Aline Fairweather

_____________________________ _____________________________

Erin Brennan Kirstin J. Miller

DECHERT PRICE & RHOADS

4000 Bell Atlantic Tower

1717 Arch Street

Philadelphia, PA 19103-2793

(215) 994-4000

Case 2:02-cv-04294-LP Document 8 Filed 10/21/2002 Page 1 of 1
Document

Exhibit 10.27




EXECUTION VERSION

AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT
THIS AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT (the “Amendment No. 2”), made and entered into this 1st day of April, 2018 (the “Effective Date”) by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company and successor to Pharmaceutical Product Development, Inc. (the “Company”), and David M. Johnston (the “Executive”).
WHEREAS, the Company and Executive are parties to that certain Employment Agreement dated as of May 22, 2013 as amended by that certain Amendment No. 1 to the Employment Agreement effective as of December 1, 2016 (the “Employment Agreement”); and
WHEREAS, the parties desire to further amend the Employment Agreement as set forth herein.
NOW, THEREFORE, that for and in consideration of the foregoing recitals, the mutual promises, covenants and conditions contained herein, and other good and valid consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:
1.Capitalized Terms. Capitalized terms used in this Amendment No. 2 and not defined herein shall have the meaning given to them in the Employment Agreement.
2.Amendment. The third sentence of Section 2(b) of the Employment Agreement be and hereby is deleted in its entirety and replaced in full by the following sentence:
“The Annual Bonus shall be based on the achievement of applicable Company and individual performance metrics set forth in or established under the Company’s Senior Executive Incentive Compensation Plan, as it may be amended from time to time.”
3.Entire Agreement. This Amendment No. 2 constitutes the entire agreement of the parties with respect to the subject matter hereof and supersedes all prior or contemporaneous agreements or understandings, whether written or oral, relating to the same.
4.Binding Effect. The Employment Agreement, as herein amended, shall continue in full force and effect.











IN WITNESS WHEREOF, the parties have executed this Amendment No. 2 as of the date first above written.
PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC
By:    /s/ B. Judd Hartman                
Name:      B. Judd Hartman                
Title:      Chief Administration Officer and General     
  Counsel 




/s/ David M. Johnston                    
David M. Johnston




Consented and agreed to by Parent:


EAGLE HOLDING COMPANY I
By:    /s/ B. Judd Hartman                
Name:       B. Judd Hartman                
Title:       General Counsel                






[Signature Page to Employment Agreement Amendment]
COURT OF APPEALS

EIGHTH DISTRICT OF TEXAS

EL PASO, TEXAS

JUAN MARTINEZ,

Appellant,

v.

THE STATE OF TEXAS,

Appellee.

§

§

§

§

§

No. 08-23-00070-CR

Appeal from the

34th Judicial District Court

of El Paso County, Texas

(TC# 20230D00029)

J U D G M E N T

The Court has considered this cause on the record and concludes there was error in the 

judgment. We therefore modify the punishment portion of the trial court’s judgment as to Juan 

Martinez’s conviction of intoxication assault causing serious bodily injury while operating a motor 

vehicle (Count III only), such that the judgment imposes a sentence of ten years’ confinement in 

TDCJ and no fine, with such term of confinement suspended and he is placed on community 

supervision for ten years. We otherwise affirm the judgment as modified. This decision shall be 

certified below for observance.

IT IS SO ORDERED THIS 7TH DAY OF OCTOBER 2023.

GINA M. PALAFOX, Justice

Before Palafox, J., Soto, J., and Marion, C.J. (Ret.)

Marion, C.J. (Ret.), sitting by assignment
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[S. 13 Introduced in Senate (IS)]

<DOC>

115th CONGRESS
  1st Session
                                 S. 13

 To amend the Internal Revenue Code of 1986 to prevent high net worth 
   individuals from receiving tax windfalls for entering government 
                                service.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                            January 3, 2017

    Mr. Whitehouse (for himself, Ms. Baldwin, Ms. Warren, and Mrs. 
  Feinstein) introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
 To amend the Internal Revenue Code of 1986 to prevent high net worth 
   individuals from receiving tax windfalls for entering government 
                                service.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``No Windfalls for Government Service 
Act''.

SEC. 2. LIFETIME LIMITATION ON NONRECOGNITION OF PROPERTY SOLD TO 
              COMPLY WITH CONFLICT-OF-INTEREST REQUIREMENTS.

    (a) In General.--Section 1043 of the Internal Revenue Code of 1986 
is amended by adding at the end the following new subsection:
    ``(d) Limitation.--The amount of gain to which subsection (a) 
applies with respect to any taxpayer for a taxable year shall not 
exceed $1,000,000 reduced by the amount of gain to which subsection (a) 
applied with respect to such taxpayer for all preceding taxable 
years.''.
    (b) Effective Date.--The amendment made by this section shall apply 
to sales in taxable years beginning after December 31, 2016.
                                 <all>
```
IN THE UNITED STATES DISTRICT COURT

FOR THE EASTERN DISTRICT OF PENNSYLVANIA

HAROLD C. WILSON : CIVIL ACTION

Plaintiff, :

v. :

 :

CITY OF PHILADELPHIA, et al. :

Defendants. : NO. 04-5396

ORDER

AND NOW, this 8 day of May, 2013, having considered the Motion for Judgement on th

the Pleadings filed by Defendant R. Seth Williams, the District Attorney of Philadelphia (Doc.

#121), Plaintiff’s response thereto (Doc. #123), Defendant’s Reply (Doc. #125), and the

arguments of counsel to the court, and for the reasons set forth in the accompanying

memorandum, it is hereby ORDERED that Defendant’s Motion for Judgement on the Pleadings

is DENIED. 

IT IS FURTHER ORDERED that the remaining claims against the individual District

Attorney Defendants (“DA Defendants”) concerning the DA Defendants’ alleged actions during

the investigation phase are dismissed with prejudice per Plaintiff’s concession at oral argument. 

See Transcript of Motion Hearing 3/22/13, at 13-14 (Doc. # 135). 

 

BY THE COURT:

 /s/ L. Felipe Restrepo 

L. FELIPE RESTREPO

UNITED STATES MAGISTRATE JUDGE